Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes: A Randomized Trial

RCT (n=225) reports median event-free survival was prolonged by approximately 1year with deferasirox vs placebo (3.9 years [95% CI, 3.2 to 4.3 yrs] vs. 3.0 years [CI 2.2 to 3.7 yrs], respectively; HR 0.64 [CI 0.42 to 0.96]).

SPS commentary:

The study included patients with serum ferritin levels greater than 2247 pmol/L, prior receipt of 15 to 75 packed red blood cell units and no severe cardiac, liver, or renal abnormalities.


Event-free survival was defined as time from date of randomisation to first documented nonfatal event (related to cardiac or liver dysfunction and transformation to acute myeloid leukaemia) or death.


Annals of Internal Medicine